Valuation: Entrada Therapeutics, Inc.

Market Cap 244M 212M 197M 181M 342M 23.29B 348M 2.33B 912M 11.57B 916M 896M 38.9B P/E 2026 *
-1.68x
P/E 2027 * -1.78x
Enterprise Value 150M 131M 121M 112M 211M 14.36B 215M 1.44B 563M 7.13B 565M 553M 23.99B EV / Sales 2026 *
10x
EV / Sales 2027 * -2.94x
Free-Float
85.73%
Yield 2026 *
-
Yield 2027 * -
1 day+3.36%
1 week+11.90%
Current month-8.02%
1 month-8.02%
3 months-49.85%
6 months-40.82%
Current year-34.14%
1 week 5.72
Extreme 5.72
7.04
1 month 5.72
Extreme 5.72
8.1
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 31/07/2017
Director of Finance/CFO 47 31/10/2020
President 56 31/12/2023
Director TitleAgeSince
Director/Board Member 50 31/07/2017
Chairman 44 30/11/2020
Director/Board Member 67 30/11/2020
Date Insider Type Main position Quantity % Market Cap.
01/03/26 Free

Chairperson

160,261 0.4193%
01/03/26 Free

Chief Financial Officer

119,851 0.3136%
01/03/26 Free

Chief Executive Officer

376,450 0.9850%
Change 5-day change 1-year change 3-year change Capi.($)
+3.36%+11.90%+1.96%-60.82% 244M
-0.81%-0.33%+27.15%+81.12% 55.23B
+1.96%-5.42%+27.99%+66.48% 53.75B
-0.11%+0.86%-15.63%-13.56% 23.48B
-1.58%-5.51%-3.51%+375.36% 22B
+2.49%-0.92%+20.31%-12.15% 19.78B
+0.05%-2.10%+27.93%-34.02% 17.44B
+0.58%-5.88%+16.30%+540.37% 14.66B
+1.16%+0.58%+51.87%+181.96% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
Average +0.18%-0.74%+30.75%+139.69% 23.37B
Weighted average by Cap. +0.12%-0.43%+27.44%+124.83%

Financials

2026 *2027 *
Net sales 14.99M 13.02M 12.09M 11.15M 21M 1.43B 21.38M 143M 56.04M 711M 56.29M 55.06M 2.39B 29.81M 25.89M 24.04M 22.17M 41.77M 2.85B 42.53M 285M 111M 1.41B 112M 109M 4.75B
Net income -176M -153M -142M -131M -246M -16.79B -251M -1.68B -657M -8.34B -660M -646M -28.04B -188M -163M -151M -140M -263M -17.91B -268M -1.79B -701M -8.89B -704M -689M -29.91B
Net Debt -93.49M -81.2M -75.41M -69.54M -131M -8.93B -133M -893M -350M -4.43B -351M -343M -14.91B -331M -288M -267M -247M -464M -31.64B -473M -3.17B -1.24B -15.72B -1.24B -1.22B -52.85B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
30/07/26 US$6.770 +3.36% 594,748
29/07/26 US$6.550 +12.35% 435,423
28/07/26 US$5.830 -4.11% 445,752
27/07/26 US$6.080 +3.93% 446,761
24/07/26 US$5.850 -3.31% 566,335
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.770USD
Average target price
18.75USD
Spread / Average Target
+176.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock